Search Results - "Noret, Marion"
-
1
Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia
Published in PLoS neglected tropical diseases (01-03-2012)“…At the end of 2005, an outbreak of fever associated with joint pain occurred in La Réunion. The causal agent, chikungunya virus (CHIKV), has been known for 50…”
Get full text
Journal Article -
2
Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study
Published in Vaccines (Basel) (27-07-2021)“…We aimed to report SARS-CoV-2 seroprevalence after the first wave of the pandemic among healthcare workers, and to explore factors associated with an increased…”
Get full text
Journal Article -
3
Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol
Published in Frontiers in public health (04-11-2022)“…The SARS-CoV-2 pandemic led to the implementation of several non-pharmaceutical interventions (NPIs), from closings of bars and restaurants to curfews and…”
Get full text
Journal Article -
4
Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France
Published in AIDS (London) (24-09-2018)“…BACKGROUND:On-demand oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) has been approved for pre-exposure prophylaxis (PrEP) in MSM in France…”
Get full text
Journal Article -
5
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Published in Clinical microbiology and infection (01-12-2021)“…We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir…”
Get full text
Journal Article -
6
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial
Published in The Lancet infectious diseases (01-05-2024)“…Staphylococcus aureus bloodstream infection is treated with at least 14 days of intravenous antimicrobials. We assessed the efficacy and safety of an early…”
Get full text
Journal Article -
7
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial
Published in Journal of antimicrobial chemotherapy (01-09-2020)“…Abstract Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a…”
Get full text
Journal Article -
8
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults
Published in BMJ open (21-09-2020)“…To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical…”
Get full text
Journal Article -
9
A Randomized Controlled Trial to Study the Transmission of SARS-CoV-2 and Other Respiratory Viruses During Indoor Clubbing Events (ANRS0066s ITOC Study)
Published in Clinical infectious diseases (15-12-2023)“…Abstract Background In the context of the circulation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) variant,…”
Get full text
Journal Article -
10
Daily or on demand oral TDF/FTC for HIV pre-exposure prophylaxis: experience from an hospital-based clinic in France
Published in AIDS (London) (12-07-2018)“…BACKGROUND:On Demand oral TDF/FTC has been approved for pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) in France following the results of…”
Get full text
Journal Article -
11
-
12
Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20–15 DisCoVeRy study
Published in Contemporary clinical trials (01-08-2023)“…Health measures taken during the pandemic deeply modified the clinical research practices. At the same time, the demand for the results of the COVID-19 trials…”
Get full text
Journal Article -
13
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Published in Clinical microbiology and infection (01-12-2021)“…Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or…”
Get full text
Journal Article -
14
-
15
Interleukin 6, RANKL, and Osteoprotegerin Expression by Chikungunya Virus-Infected Human Osteoblasts
Published in The Journal of infectious diseases (01-08-2012)Get full text
Journal Article -
16
Chikungunya physiopathology: Infection data from acute to chronic phase
Published in Virologie (Montrouge, France) (01-08-2011)Get full text
Journal Article -
17
Physiopathologie du chikungunya: les marqueurs de l'infection de la phase aiguë à l'atteinte chronique
Published in Virologie (Montrouge, France) (01-07-2011)Get full text
Journal Article